Welcome to our dedicated page for Viemed Healthcare SEC filings (Ticker: VMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Viemed Healthcare, Inc. (VMD) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, along with AI-generated summaries to help interpret complex documents. Viemed is incorporated in British Columbia, Canada and files with the SEC under Commission File Number 001-38973, with its common shares listed on NASDAQ under the symbol VMD.
For a company operating as an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, core filings such as the annual report on Form 10-K and quarterly reports on Form 10-Q are central resources. These documents typically contain detailed information on revenue from respiratory equipment and services, operating expenses, cash flows, and risk factors relevant to its non-invasive ventilation, sleep therapy, oxygen therapy, staffing, and related activities.
Viemed also files frequent current reports on Form 8-K to disclose material events. Recent 8-K filings have covered quarterly and year-to-date financial results, the completion of a share repurchase program, the acquisition of Lehan’s Medical Equipment, and amendments to the company’s credit agreement that extend certain term loan commitment expiration dates and provide technical changes. Some 8-K filings also furnish investor presentations and financial supplements used in communications with analysts and investors.
On this page, users can review Form 4 and other insider transaction filings, where available, alongside periodic and current reports. Stock Titan’s AI tools summarize lengthy filings, highlight key sections, and surface items such as changes to credit facilities, capital allocation actions, and updates to financial guidance that Viemed has chosen to disclose. Real-time updates from EDGAR ensure that new Viemed filings appear promptly, while AI-generated insights are designed to make the company’s regulatory record more accessible to both experienced and newer investors.
Viemed Healthcare, Inc. President Michael Moore reported open-market sales of Common Shares indirectly held through Moore Faster LLC. The LLC sold 31,570 shares on March 18 at a weighted-average price of $9.42, 40,232 shares on March 19 at $9.21, and 65,000 shares on March 20 at $8.77 per share. Footnotes state each reported price is a weighted average for multiple trades in ranges of $9.26–$9.61, $9.04–$9.38, and $8.63–$9.18, respectively. Following these transactions, Moore Faster LLC held 1,585,812 Common Shares indirectly, and Michael Moore also held 189,090 Common Shares directly.
Morgan Stanley Smith Barney LLC submitted a notice under Rule 144 regarding the proposed sale of 65,000 shares of Common stock of the issuer. The filing identifies MOORE FASTER LLC as a selling holder with recent sales reported on 03/19/2026 and 03/18/2026.
The filing lists two recent transactions by MOORE FASTER LLC: 40,232 shares sold on 03/19/2026 and 31,570 shares sold on 03/18/2026, with cash amounts shown alongside each sale.
VMD reported a Form 144 disclosing a sale of 31,570 common shares by MOORE FASTER LLC on 03/18/2026. The reported proceeds were $297,345.20. The transaction lists Morgan Stanley Smith Barney LLC as the broker/financial intermediary.
Viemed Healthcare used a new investor presentation to highlight strong 2025 performance and 2026 guidance. For 2025, the company reported $270M in net revenue, $61M Adjusted EBITDA, $28M free cash flow, nine straight years of positive net income, and effectively $0M net debt.
The business is increasingly diversified, with sleep representing 21% of Q4 2025 net revenue and showing 62% year-over-year growth in PAP therapy patients and 49% growth in sleep resupply patients. Management is guiding 2026 net revenue to $310M–$320M and Adjusted EBITDA to $65M–$69M, with net capex of 10%–11.5% of net revenue.
The company emphasizes a capital-light, home-based care model, expanding from complex ventilation into sleep, oxygen, airway clearance, women’s health and staffing. With more than 172,000 patients across all 50 states, $46M of credit facility availability, and a newly authorized share repurchase program covering up to 5% of shares outstanding, Viemed presents itself as a growth platform supported by regulatory stability and a strong balance sheet.
Viemed Healthcare, Inc. outlines its 2025 annual business profile as a U.S. home medical equipment and post-acute care provider focused on respiratory, chronic care, and women’s health services. The company serves patients in all 50 states through a high-touch, technology-enabled home-care model.
Viemed employed 1,382 people as of December 31, 2025, including 401 licensed respiratory therapists. Monthly ventilator rentals generated about 51% of 2025 revenue, while Medicare and Medicaid together provided 40%. Non-affiliate market value was $238,786,569, with 38,602,631 common shares outstanding.
The report emphasizes heavy dependence on government and commercial reimbursement, extensive U.S. healthcare regulation, fraud and abuse laws, HIPAA privacy and cybersecurity obligations, and evolving Medicare coverage and competitive bidding rules that could materially affect utilization, pricing, and growth, especially for ventilator and home-based respiratory services.
Viemed Healthcare reported record 2025 results with net revenue of $270.3 million, up 21% from 2024, driven by organic growth and its Lehan's Medical Equipment acquisition. Net income attributable to Viemed rose 33% to $14.9 million, and Adjusted EBITDA reached a record $61.4 million.
The company generated strong free cash flow of $28.1 million for 2025, up sharply from $11.6 million, while ventilator, PAP therapy, and sleep resupply patient counts all increased. For 2026, Viemed guides net revenue to $310–$320 million and Adjusted EBITDA to $65–$69 million. The board also approved a new share repurchase program for up to 1,930,131 common shares, about 5% of shares outstanding, effective through March 2027.
Viemed Healthcare Chief Executive Officer and director Hoyt Casey reported equity compensation-related transactions on common shares dated January 29, 2026. He acquired 39,795 common shares through the vesting and settlement of Restricted Stock Units and 13,265 common shares tied to cash-settled phantom share units.
The company withheld 13,913 common shares at a per-share value of $7.48 to cover Casey’s tax obligations from RSU vesting, and 13,265 common shares were simultaneously disposed of to the company in connection with phantom share settlement. After these transactions, Casey directly owned 350,464 common shares and indirectly held 1,984,943 common shares through Elizabeth Rose Homes LLC.
Viemed Healthcare vice president of sales Jerome Cambre reported equity award vesting and related share movements. On January 29, 2026, 8,619 Restricted Stock Units converted into common shares and 2,873 phantom share units vested into common shares. To cover taxes from RSU vesting, the issuer withheld 2,355 common shares at a per-share value of $7.48, based on the market closing price that day. Following the reported transactions, Cambre directly held 104,088 Viemed common shares.
Viemed Healthcare president Michael Moore reported equity award vesting and related share movements. On January 29, 2026, 26,842 Restricted Stock Units converted into an equal number of common shares, and 8,947 phantom share units vested and were economically settled for common shares before being delivered back to the company for cash.
The issuer withheld 7,342 common shares at $7.48 per share to cover Moore’s tax obligations from the RSU vesting. After these transactions, Moore held 189,090 common shares directly and 1,722,614 common shares indirectly through Moore Faster LLC.